SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) will host a convention name and stay webcast on Monday, October 17, 2022 at 8:00 a.m. ET (5:00 a.m. PT) to focus on topline efficacy and security outcomes from its CATALINA Phase 2 trial of NGM621 in sufferers with geographic atrophy secondary to age-related macular degeneration.
To entry the stay webcast and slides, please go to the “Investors & Media” part of NGM Bio’s web site at https://ir.ngmbio.com/. The webcast can be archived for 30 days.
About NGM Bio
NGM Bio is targeted on discovering and growing novel, life-changing medicines for folks whose well being and lives have been disrupted by illness. The firm’s biology-centric drug discovery method goals to seamlessly combine interrogation of complicated disease-associated biology and protein engineering experience to unlock proprietary insights which can be leveraged to generate promising product candidates and allow their speedy development into proof-of-concept research. As explorers on the frontier of life-changing science, NGM Bio aspires to function some of the productive analysis and improvement engines within the biopharmaceutical trade. All therapeutic candidates within the NGM Bio pipeline have been generated by its in-house discovery engine, at all times led by biology and motivated by unmet affected person want. Today, the corporate has seven applications in scientific improvement, together with 4 in Phase 2 or 2b research, together with the lately accomplished NGM621 CATALINA trial, throughout three therapeutic areas: most cancers, retinal illnesses and liver and metabolic illnesses. Visit us at www.ngmbio.com for extra info.
